Plasma metabolomics identifies key metabolites and improves the prediction of benign prostatic hyperplasia

These findings highlight the associations between circulating metabolites and the hazard of BPH, supporting the potential of NMR-based metabolomics to enhance risk prediction and inform clinical management strategies.